Immix Biopharma Stock Piotroski F Score

IMMX Stock  USD 1.80  0.02  1.10%   
This module uses fundamental data of Immix Biopharma to approximate its Piotroski F score. Immix Biopharma F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Immix Biopharma. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Immix Biopharma financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Immix Biopharma Altman Z Score, Immix Biopharma Correlation, Immix Biopharma Valuation, as well as analyze Immix Biopharma Alpha and Beta and Immix Biopharma Hype Analysis.
For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.
  
At this time, Immix Biopharma's Debt To Equity is fairly stable compared to the past year. Debt Equity Ratio is likely to rise to 0 in 2025, whereas Short and Long Term Debt Total is likely to drop slightly above 42.8 K in 2025. At this time, Immix Biopharma's PTB Ratio is fairly stable compared to the past year. Book Value Per Share is likely to rise to 0.88 in 2025, whereas Free Cash Flow Yield is likely to drop (0.11) in 2025.
At this time, it appears that Immix Biopharma's Piotroski F Score is Unavailable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Unavailable
Current Return On Assets

Negative

Focus
Change in Return on Assets

Decreased

Focus
Cash Flow Return on Assets

Negative

Focus
Current Quality of Earnings (accrual)

Improving

Focus
Asset Turnover Growth

Decrease

Focus
Current Ratio Change

Decrease

Focus
Long Term Debt Over Assets Change

N/A

Focus
Change In Outstending Shares

Decrease

Focus
Change in Gross Margin

No Change

Focus

Immix Biopharma Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Immix Biopharma is to make sure Immix is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Immix Biopharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Immix Biopharma's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.80.9
Fairly Down
Slightly volatile
Total Current Liabilities2.4 M3.3 M
Way Down
Slightly volatile
Total Assets12 M22.9 M
Way Down
Slightly volatile
Total Current Assets12 M22.8 M
Way Down
Slightly volatile

Immix Biopharma F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Immix Biopharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Immix Biopharma in a much-optimized way.

About Immix Biopharma Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value Per Share

0.88

At this time, Immix Biopharma's Book Value Per Share is fairly stable compared to the past year.

About Immix Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Immix Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immix Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immix Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.